Special Issue

Humanized Mice in Vaccinology: Opportunities and Challenges in 2021

Message from the Guest Editors

In this Special Issue, we will discuss all aspects related to the use of humanized mice in vaccinology and discuss the opportunities and the challenges ahead. Keywords:

- humanized mice
- vaccine
- viruses
- cancer vaccines
- dendritic cell vaccines
- T cells
- emerging viruses
- persistent viruses
- immunogenicity
- NSG
- BLT
- uPA
- xenografts

Guest Editors

Dr. Estefanía Rodríguez

Bernhard Nocht Institute for Tropical Medicine, Virology Department, Bernhard Nocht Strasse 74, 20359 Hamburg, Germany

Dr. César Muñoz-Fontela

Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany

Deadline for manuscript submissions

closed (28 February 2022)



an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



mdpi.com/si/60230

Vaccines MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 vaccines@mdpi.com

mdpi.com/journal/

vaccines





an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



vaccines



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).